Switching from Aripiprazole to Lurasidone
Recommended Cross-Taper Strategy
- The American College of Psychiatry recommends starting lurasidone at 40mg daily with food while simultaneously beginning a gradual taper of aripiprazole, reducing it by 50% during week 1, then discontinuing by the end of week 2, as this approach is supported by evidence showing comparable safety and tolerability to delayed tapering strategies 1
Critical Administration Requirements
- Lurasidone must be taken with food (at least 350 calories) to ensure adequate absorption, as failure to take with food significantly reduces bioavailability and therapeutic efficacy 2
Monitoring and Assessment
- Evaluate treatment response and tolerability at week 4 to determine if dose adjustment is needed, and monitor for akathisia, sedation, and gastrointestinal symptoms 1
- Assess positive symptoms, mood symptoms, and functional status regularly, and perform movement disorder screening, though lurasidone shows low risk for extrapyramidal symptoms 1
Important Clinical Considerations
- Switching from a D2 partial agonist (aripiprazole) to a D2 antagonist (lurasidone) represents a change in pharmacodynamic profile, which is appropriate when first-line treatment is inadequate, and aligns with guideline recommendations to try agents with different receptor profiles when initial treatment fails 1
- If significant symptoms persist after 4 weeks at therapeutic lurasidone doses with confirmed adherence, reassess diagnosis and consider alternative strategies 1